Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6
July 30, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting
June 22, 2020 07:00 ET
|
Autolus Therapeutics plc
- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate - AUTO6NG in small cell lung cancer – in vitro and in...
Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress
June 12, 2020 02:30 ET
|
Autolus Therapeutics plc
Pivotal AUTO1 study in adult ALL patients enrolling - AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and...
Autolus Therapeutics reschedules its investor EHA conference call
June 08, 2020 17:00 ET
|
Autolus Therapeutics plc
LONDON, June 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
May 29, 2020 07:37 ET
|
Autolus Therapeutics plc
– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile – Conference call and webcast to be held Monday, June...
Autolus Therapeutics to host Investor Conference Calls through June
May 26, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 26, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020
May 22, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...
Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting
May 15, 2020 11:20 ET
|
Autolus Therapeutics plc
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held Thursday, June 25,...
Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting
May 15, 2020 07:00 ET
|
Autolus Therapeutics plc
– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held...
Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program
May 14, 2020 07:00 ET
|
Autolus Therapeutics plc
- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30...